论文部分内容阅读
目的:探讨重组人β2糖蛋白1第一结构域(hrβ2GPⅠDⅠ)对抗磷脂抗体综合征(APS)患者血清诱导人脐静脉内皮细胞产生细胞间黏附分子1(ICAM1)、单核细胞趋化蛋白1(MCP1)的影响。方法:应用hrβ2GPⅠDⅠ二聚体处理前后的APS患者血清分别与人脐静脉内皮细胞(HUVEC)共孵育,细胞ELISA和RTPCR方法分析处理前后HUVEC表达ICAM1、MCP1的变化。结果:hrβ2GPⅠDⅠ二聚体处理后的APS患者血清较处理前相比,与其孵育的HUVEC表达ICAM1、MCP1在蛋白和mRNA水平均明显降低。结论:hβ2GPⅠDⅠ可中和APS患者血清中的大部分致病性抗β2GPⅠ抗体(anti-β2GPⅠ)。
OBJECTIVE: To investigate the effect of hrβ2GPⅠDⅠ on the expression of intercellular adhesion molecule-1 (ICAM1), monocyte chemoattractant protein 1 (ICAM1) in human umbilical vein endothelial cells induced by serum of patients with antiphospholipid antibody syndrome (APS) MCP1). Methods: The serum of APS patients before and after treatment with hrβ2GPⅠDⅠ dimer was co-incubated with human umbilical vein endothelial cells (HUVECs). The expression of ICAM1 and MCP1 in HUVECs were analyzed by ELISA and RTPCR. Results: Compared with the pre-treatment, the expression of ICAM1 and MCP1 in HUVECs incubated with hrβ2GPⅠDⅠ dimer decreased significantly at protein and mRNA levels. Conclusion: hβ2GPⅠDⅠ can neutralize most of the pathogenic anti-β2GPⅠ antibodies (anti-β2GPⅠ) in serum of APS patients.